Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer March 17, 2026 3:00 PM EDT
Company Participants
Christian Behrenbruch – Co-Founder, MD, Group CEO & Executive Director
David Cade – Group Chief Medical Officer
Conference Call Participants
Robert Burns – H.C. Wainwright & Co, LLC, Research Division
Presentation
Robert Burns
H.C. Wainwright & Co, LLC, Research Division
Thank you for joining us today. I’m Robert Burns, the Managing Director and Senior Biotech Analyst at H.C. Wainwright. I’m joined today by Chris Behrenbruch, the CEO of Telix; and David Cade, the CMO of Telix. Gentlemen, thank you for joining us today.
Christian Behrenbruch
Co-Founder, MD, Group CEO & Executive Director
Thanks very much. Good to see you, Robbie.
Robert Burns
H.C. Wainwright & Co, LLC, Research Division
Awesome. So why don’t we just dive in?
Question-and-Answer Session
Robert Burns
H.C. Wainwright & Co, LLC, Research Division
For those who may be unfamiliar with Telix, can you give us a brief overview of the company and give us a recap of your 2025 earnings that led to a strong year-over-year growth as well as the disease areas that you’re focused on?
Christian Behrenbruch
Co-Founder, MD, Group CEO & Executive Director
Yes. Thanks. So we’re a fully vertically integrated radiopharma company specializing in oncology. We have a portfolio of focus in urologic oncology and neuro-oncology in particular. We are a commercial stage company. This past year, we did just over $800 million in sales, primarily around our U.S. prostate cancer imaging franchise. That’s our — we have two approved FDA-approved products in that space and very active product portfolio on the therapy trials, which I’m sure we’ll get to at some point as well.
But in terms of commercial performance, we’ve just put out our guidance for